BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, Ye Q, Huang DQ, Zhao C, Zhang J, Liu C, Chang N, Xing F, Yan S, Hui WZ, Sook Yee NT, Mayumi M, Liu X, Liu C, Rui F, Yang H, Yang Y, Jin R, Le RHX, Xu Y, Le DM, Barnett S, Stave CD, Cheung R, Zhu Q, Nguyen MH. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01280-5. [PMID: 34890795 DOI: 10.1016/j.cgh.2021.12.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 33.0] [Reference Citation Analysis]
Number Citing Articles
1 Tian L, Zhao R, Xu X, Zhou Z, Xu X, Luo D, Zhou Z, Liu Y, Kushmaro A, Marks RS, Dinnyés A, Sun Q. Modulatory effects of Lactiplantibacillus plantarum on chronic metabolic diseases. Food Science and Human Wellness 2023;12:959-974. [DOI: 10.1016/j.fshw.2022.10.018] [Reference Citation Analysis]
2 Amangurbanova M, Huang DQ, Loomba R. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD. Aliment Pharmacol Ther 2022. [DOI: 10.1111/apt.17292] [Reference Citation Analysis]
3 Volpe S, Lisco G, Fanelli M, Racaniello D, Colaianni V, Triggiani D, Donghia R, Crudele L, Rinaldi R, Sabbà C, Triggiani V, De Pergola G, Piazzolla G. Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. Nutrients 2022;14:4673. [DOI: 10.3390/nu14214673] [Reference Citation Analysis]
4 Zhou S, Chen J, Yang S, Pan Y, Feng X, Ma S, Fan F, Gong S, Wang Y, Chen P, Chu Q. Pu'er raw tea extract alleviates lipid deposition in both LO2 cells and Caenorhabditis elegans. Food Bioscience 2022. [DOI: 10.1016/j.fbio.2022.102172] [Reference Citation Analysis]
5 Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, Tan DJH, Tang ASP, Tay P, Xiao J, Yong JN, Zeng RW, Chew NWS, Nah B, Kulkarni A, Siddiqui MS, Dan YY, Wong VW, Sanyal AJ, Noureddin M, Muthiah M, Ng CH. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00317-x] [Reference Citation Analysis]
6 Lonardo A, Mantovani A, Targher G, Baffy G. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications. IJMS 2022;23:13320. [DOI: 10.3390/ijms232113320] [Reference Citation Analysis]
7 Lee JH, Kwon YJ, Lee HS, Han JH, Joung B, Kim SJ. Fatty Liver Is an Independent Risk Factor for Elevated Intraocular Pressure. Nutrients 2022;14. [PMID: 36364718 DOI: 10.3390/nu14214455] [Reference Citation Analysis]
8 Theofilis P, Vordoni A, Kalaitzidis RG. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations. World J Gastroenterol 2022; 28(39): 5691-5706 [DOI: 10.3748/wjg.v28.i39.5691] [Reference Citation Analysis]
9 Tan C, Chan KE, Ng CH, Tseng M, Syn N, Tang ASP, Chin YH, Lim WH, Tan DJH, Chew N, Ong EYH, Koh TK, Xiao J, Chee D, Valsan A, Siddiqui MS, Huang D, Noureddin M, Wijarnpreecha K, Muthiah MD. DEXA Scan Body Fat Mass Distribution in Obese and Non-Obese Individuals and Risk of NAFLD-Analysis of 10,865 Individuals. J Clin Med 2022;11. [PMID: 36294526 DOI: 10.3390/jcm11206205] [Reference Citation Analysis]
10 Wang X, Wang A, Zhang R, Cheng S, Pang Y. Associations between Healthy Lifestyle and All-Cause Mortality in Individuals with Metabolic Associated Fatty Liver Disease. Nutrients 2022;14:4222. [DOI: 10.3390/nu14204222] [Reference Citation Analysis]
11 Lv J, Xing C, Chen Y, Bian H, Lv N, Wang Z, Liu M, Su L. The STING in Non-Alcoholic Fatty Liver Diseases: Potential Therapeutic Targets in Inflammation-Carcinogenesis Pathway. Pharmaceuticals (Basel) 2022;15. [PMID: 36297353 DOI: 10.3390/ph15101241] [Reference Citation Analysis]
12 Ng CH, Xiao J, Chew NWS, Chin YH, Chan KE, Quek J, Lim WH, Tan DJH, Loke RWK, Tan C, Tang ASP, Goh XL, Nah B, Syn N, Young DY, Tamaki N, Huang DQ, Siddiqui MS, Noureddin M, Sanyal A, Muthiah M. Depression in non-alcoholic fatty liver disease is associated with an increased risk of complications and mortality. Front Med (Lausanne) 2022;9:985803. [PMID: 36275825 DOI: 10.3389/fmed.2022.985803] [Reference Citation Analysis]
13 Bellini MI, Urciuoli I, Del Gaudio G, Polti G, Iannetti G, Gangitano E, Lori E, Lubrano C, Cantisani V, Sorrenti S, D’Andrea V. Nonalcoholic fatty liver disease and diabetes. World J Diabetes 2022; 13(9): 668-682 [DOI: 10.4239/wjd.v13.i9.668] [Reference Citation Analysis]
14 Xie Y, Kong W, Wang X, Wu Z. Association of glycated hemoglobin with non-alcoholic fatty liver disease patients and the severity of liver steatosis and fibrosis measured by transient elastography in adults without diabetes. BMC Endocr Disord 2022;22. [DOI: 10.1186/s12902-022-01134-z] [Reference Citation Analysis]
15 Ng CH, Nah B, Kaewdech A, Aung HB, Mak L, Kulkarni AV, Muthiah M. Factors Associated with Risk of NAFLD and Progression in Multiethnic Asians. A Latent Class and Machine Learning Analysis.. [DOI: 10.21203/rs.3.rs-1968295/v1] [Reference Citation Analysis]
16 Montemayor S, Mascaró CM, Ugarriza L, Casares M, Gómez C, Martínez JA, Tur JA, Bouzas C. Intrahepatic Fat Content and COVID-19 Lockdown in Adults with NAFLD and Metabolic Syndrome. Nutrients 2022;14:3462. [DOI: 10.3390/nu14173462] [Reference Citation Analysis]
17 Zunica ERM, Heintz EC, Axelrod CL, Kirwan JP. Obesity Management in the Primary Prevention of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:4051. [PMID: 36011044 DOI: 10.3390/cancers14164051] [Reference Citation Analysis]
18 Ng CH, Wong ZY, Chew NWS, Chan KE, Xiao J, Sayed N, Lim WH, Tan DJH, Loke RWK, Tay PWL, Yong JN, Kong G, Huang DQ, Wang J, Chan M, Dalakoti M, Tamaki N, Noureddin M, Siddiqui MS, Sanyal AJ, Muthiah M. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.942753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Harrison SA, Ruane PJ, Freilich B, Neff G, Patil R, Behling C, Hu C, Shringarpure R, de Temple B, Fong E, Tillman EJ, Rolph T, Cheng A, Yale K. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100563] [Reference Citation Analysis]
20 Liu Z, Suo C, Fan H, Zhang T, Jin L, Chen X. Dissecting causal relationships between nonalcoholic fatty liver disease proxied by chronically elevated alanine transaminase levels and 34 extrahepatic diseases. Metabolism 2022;:155270. [PMID: 35914620 DOI: 10.1016/j.metabol.2022.155270] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
21 Forlano R, Sivakumar M, Mullish BH, Manousou P. Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review. IJMS 2022;23:8307. [DOI: 10.3390/ijms23158307] [Reference Citation Analysis]
22 Liao S, An K, Liu Z, He H, An Z, Su Q, Li S. Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China. J Clin Lab Anal 2022;:e24626. [PMID: 35881683 DOI: 10.1002/jcla.24626] [Reference Citation Analysis]
23 Jinato T, Chayanupatkul M, Dissayabutra T, Chutaputti A, Tangkijvanich P, Chuaypen N. Litchi-Derived Polyphenol Alleviates Liver Steatosis and Gut Dysbiosis in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Double-Blinded, Placebo-Controlled Study. Nutrients 2022;14:2921. [PMID: 35889878 DOI: 10.3390/nu14142921] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Lonardo A, Mantovani A, Petta S, Carraro A, Byrne CD, Targher G. Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. Nat Rev Endocrinol 2022. [PMID: 35840803 DOI: 10.1038/s41574-022-00711-5] [Reference Citation Analysis]
25 Maev IV, Andreev DN, Kucheryavyy YA. Metabolically associated fatty liver disease – a disease of the 21st century: A review. Consilium Medicum 2022;24:325-332. [DOI: 10.26442/20751753.2022.5.201532] [Reference Citation Analysis]
26 Ilia S, Monica V, Daniel S. Mean nocturnal baseline impedance and endoscopic mucosal impedance measurements in patients with eosinophilic esophagitis: a new tool for follow up and management? Updates Surg 2022. [PMID: 35840790 DOI: 10.1007/s13304-022-01331-4] [Reference Citation Analysis]
27 Rivera-Andrade A, Petrick JL, Alvarez CS, Graubard BI, Florio AA, Kroker-Lobos MF, Parisi D, Freedman ND, Lazo M, Guallar E, Groopman JD, Ramirez-Zea M, McGlynn KA. Circulating bile acid concentrations and non-alcoholic fatty liver disease in Guatemala. Aliment Pharmacol Ther 2022;56:321-9. [PMID: 35484638 DOI: 10.1111/apt.16948] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
28 Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG, Shaheen A. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00165-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
29 Dearlove DJ, Hodson L. Intrahepatic triglyceride content: influence of metabolic and genetics drivers. Curr Opin Clin Nutr Metab Care 2022;25:241-7. [PMID: 35762159 DOI: 10.1097/MCO.0000000000000838] [Reference Citation Analysis]
30 Mantovani A, Lombardi R, Cattazzo F, Zusi C, Cappelli D, Dalbeni A. MAFLD and CKD: An Updated Narrative Review. IJMS 2022;23:7007. [DOI: 10.3390/ijms23137007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Androutsakos T, Voulgaris TA, Bakasis A, Koutsompina M, Chatzis L, Argyropoulou OD, Pezoulas V, Fotiadis DI, Papatheodoridis G, Tzioufas AG, Goules AV. Liver Fibrosis in Primary Sjögren’s Syndrome. Front Immunol 2022;13:889021. [DOI: 10.3389/fimmu.2022.889021] [Reference Citation Analysis]
32 Huang DQ, Singal AG, Kono Y, Tan DJ, El-serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metabolism 2022. [DOI: 10.1016/j.cmet.2022.05.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
33 Lee KS, Cho Y, Kim H, Hwang H, Cho JW, Lee Y, Lee S. Association of Metabolomic Change and Treatment Response in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines 2022;10:1216. [DOI: 10.3390/biomedicines10061216] [Reference Citation Analysis]
34 Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, Tan DJH, Lim WH, Lin SY, Huang D, Chan M, Khoo CM, Chew NWS, Kaewdech A, Chamroonkul N, Dan YY, Noureddin M, Muthiah M, Eslam M, Ng CH. Global Prevalence and Clinical Characteristics of Metabolic Associated Fatty Liver Disease. A Meta-Analysis and Systematic Review of 10,739,607 Individuals. J Clin Endocrinol Metab 2022:dgac321. [PMID: 35587339 DOI: 10.1210/clinem/dgac321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
35 Mantovani A, Dalbeni A. Recent Developments in NAFLD. Int J Mol Sci 2022;23:2882. [PMID: 35270024 DOI: 10.3390/ijms23052882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00078-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 24.0] [Reference Citation Analysis]
37 Li J, Cheung R. Nonalcoholic Fatty Liver Disease in Children: where are we? Clin Gastroenterol Hepatol 2022:S1542-3565(22)00132-X. [PMID: 35149222 DOI: 10.1016/j.cgh.2022.02.008] [Reference Citation Analysis]
38 Tripodi A, Lombardi R, Primignani M, La Mura V, Peyvandi F, Fracanzani AL. Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. Biomedicines 2022;10:249. [PMID: 35203457 DOI: 10.3390/biomedicines10020249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]